Page last updated: 2024-11-04

vorinostat and Carcinoma, Large Cell

vorinostat has been researched along with Carcinoma, Large Cell in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Carcinoma, Large Cell: A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jones, DR1
Moskaluk, CA1
Gillenwater, HH1
Petroni, GR1
Burks, SG1
Philips, J1
Rehm, PK1
Olazagasti, J1
Kozower, BD1
Bao, Y1

Trials

1 trial available for vorinostat and Carcinoma, Large Cell

ArticleYear
Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:11

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers,

2012